Wednesday, December 16, 2020 Daily Archives

AAV Suspension Platform Generations: Continuous Improvement Leading to Increased Viral Vector Titer and Yield

by

This webcast features: Yiyu Dong, Head of Cell Line Development, and David Barnard, Senior Scientist, Process and Technology Development, WuXi Advanced Therapies The field of gene therapy has experienced significant growth in recent years. Adenoassociated virus (AAV)–mediated therapies account for ~70% of the gene therapy market. However, the manufacturing capacity for AAV vectors remains a critical bottleneck. WuXi Advanced Therapies launched a world-class AAV suspension platform early 2020. In this webinar, we will reveal the improvements that increased viral vector…

December 16, 2020

Enabling Vaccine Production: Solving Challenges

by

Vaccine developers are in need of more efficient and cost-effective approaches to manufacturing. To achieve this, we actively collaborate with academia, researchers and manufacturers to develop and optimize innovative tools, processes and strategies to resolve bottlenecks and accelerate the availability of vaccines to the global population. This e-book contains a series of case studies highlighting our recent collaborations with organizations and thought leaders on the front lines of the battle against challenging pathogens. From proof-of-concept to full commercial-scale manufacturing, discover…

December 16, 2020

Eli Lilly $880m Prevail buy a ‘good entry point’ into gene therapy

by

As Eli Lilly agrees to buy Prevail Therapeutics adding a pipeline of neuroscience assets, CEO Dave Ricks hints at further acquisitions in the gene therapy space. The deal announced yesterday will see Eli Lilly pay approximately $880 million upfront for New York-based Prevail Therapeutics, with a further $160 million set to be paid upon the first approval of a product. Prevail, launched in 2017, is developing gene therapies to slow or stop the underlying disease process for patients with neurodegenerative…

December 16, 2020